<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930773</url>
  </required_header>
  <id_info>
    <org_study_id>ONSIDE TEST</org_study_id>
    <secondary_id>Klub 30, 2012</secondary_id>
    <nct_id>NCT01930773</nct_id>
  </id_info>
  <brief_title>Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)</brief_title>
  <acronym>ONSIDE TEST</acronym>
  <official_title>Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing percutaneous coronary intervention with a residual high platelet
      reactivity despite oral clopidogrel are at increased risk of ischaemic complications. The
      strategies to overcome the issue consist of switch to a more potent antiplatelet medications
      including prasugrel or ticagrelor. Economic constrains of many countries still do not allow
      wide reimbursement of newer antiplatelet agents. Therefore a strategy to personalise
      treatment according to genotype and phenotype characteristics of the patient may provide an
      attractive solution combining high clinical efficacy with low budget impact.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Peak creatine kinase muscle brain (CK-MB) elevation</measure>
    <time_frame>Within 24 hours after Percutaneous Coronary Intervention (PCI)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The maximum level of CK-MB elevation within 24 hours of elective PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having periprocedural myocardial infarction (MI)</measure>
    <time_frame>Within 24 hours or PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>Periprocedural MI is defined as a CK-MB elevation greater than 3x of the upper limit of norm (ULN) within 24 hours of elective PCI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak troponin elevation</measure>
    <time_frame>Within 24 hours of PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>The level of peak troponin-I elevation during 24 hours of elective PCI</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with peri-procedural MI</measure>
    <time_frame>Within 24 hours of PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of peri-procedural MI defined as a peak troponin-I value greater than 5x the ULN within 24 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>BARC type 3 and 5 bleeding</measure>
    <time_frame>Within 1 week of PCI</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>BARC-defined type 3 (clinical, laboratory, and/or imaging evidence of bleeding, with healthcare provider responses) and type 5 (fatal) bleeds happening within 7 days of PCI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Death, MI, stent thrombosis (ST) or urgent repeat revascularization</measure>
    <time_frame>30 days after PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of cardiac death, myocardial infarction, definite or probable stent thrombosis or urgent repeat revascularization within 30 days of elective PCI.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Genotyping Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapid genotyping to select optimal P2Y12-inhibitor for PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotying Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular approach for performing elective PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <description>Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.</description>
    <arm_group_label>Genotyping Arm</arm_group_label>
    <other_name>Spartan rapid genotyping device to screen CYP2C19 *2 carriage in patients in the Genotyping Arm.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phenotyping</intervention_name>
    <description>Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.</description>
    <arm_group_label>Phenotying Arm</arm_group_label>
    <other_name>VerifyNow P2Y12 assay to test the response to clopidogrel.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75

          -  elective PCI

        Exclusion Criteria:

          -  acute coronary syndrome (troponin &gt; 1 x ULN),

          -  administration of glycoprotein IIb/IIIa inhibitors,

          -  chronic total occlusion,

          -  lesions with extensive calcifications requiring rotational atherectomy,

          -  platelet count &lt;70 000 /µl

          -  high bleeding risk,

          -  coronary bypass surgery in the previous 3 months,

          -  severe chronic renal failure (eGFR &lt; 30 mL/min)

          -  requirement for warfarin, dabigatran, apixaban, rivaroxaban

          -  history of stroke or TIA,

          -  weight &lt; 60 kg

          -  known bleeding diathesis,

          -  hematocrit of &lt; 30% or &gt;52%

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukasz Koltowski, MD</last_name>
    <email>lukasz@koltowski.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Aradi, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Balatonfüred</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Department of Cardiology, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Koltowski, MD</last_name>
      <email>lukasz@koltowski.com</email>
    </contact>
    <investigator>
      <last_name>Lukasz Koltowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>August 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Łukasz Kołtowski</investigator_full_name>
    <investigator_title>Cardiology Researcher</investigator_title>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>platelet function testing</keyword>
  <keyword>genotyping</keyword>
  <keyword>peri-procedural MI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
